Genetic factors associated with drug-resistance of epilepsy: Relevance of stratification by patient age and aetiology of epilepsy

@article{Snchez2010GeneticFA,
  title={Genetic factors associated with drug-resistance of epilepsy: Relevance of stratification by patient age and aetiology of epilepsy},
  author={M. Blanca S{\'a}nchez and Jos{\'e} Luis Herranz and Carlos Leno and Rosa Arteaga and Agust{\'i}n Oterino and Elsa Mar{\'i}a Valdiz{\'a}n and Josep Mar{\'i}a Nicol{\'a}s and Javier Ad{\'i}n and Juan A. Armijo},
  journal={Seizure},
  year={2010},
  volume={19},
  pages={93-101}
}
View on Elsevier
seizure-journal.com
70 Citations
Highly Influential Citations
6
Background Citations
25
Methods Citations
1
Results Citations
4

Tables from this paper

70 Citations

ABCB1 Polymorphisms and Drug-Resistant Epilepsy in a Tunisian Population
TLDR
The response to antiepileptics seems to be modulated by TT genotypes, T alleles, and the predicted haplotypes for the tested SNPs in the population.
CYP3A5∗3 and C3435T MDR1 Polymorphisms in Prognostication of Drug-Resistant Epilepsy in Children and Adolescents
TLDR
The study failed to corroborate association between polymorphism CYP3A5∗3 and C3435T polymorphism in MDR1 gene and pharmacoresistant epilepsy and do not confirm the prognostic value of the polymorphisms examined in the prognostication of drug resistance in epilepsies.
Correlation between ABCB1 gene polymorphisms, antiepileptic drug concentrations and treatment response
TLDR
In this study, an association of CT variant in ABCB1 C129T with lower AED plasmatic concentrations and no association betweenABCB1 variants and the drug responsiveness is found.
Correlation between ABCB 1 gene polymorphisms , antiepileptic drug concentrations and treatment response
Aim: A possible molecular mechanism of clinically defined multidrug-resistant epilepsy involves drug efflux transporters such as P glycoprotein (P-gp), a member of the ATPbinding cassette subfamily…
Lack of association of ABCB1 and PXR polymorphisms with response to treatment in epilepsy
Association analysis of intractable epilepsy with C3435T and G2677T/A ABCB1 gene polymorphisms in Iranian patients
TLDR
Iranian adult female patients with a C/C genotype at position 3435 of the ABCB1 gene have a higher risk of resistance to antiepileptic drugs.
ABCB1 gene polymorphisms is not associated with drug-resistant epilepsy in Romanian children
TLDR
The results show that MDR1 C1236T and G2677T polymorphisms are not associated with drug-resistant epilepsy in the study population, but 1236TT and 1236CT genotype variants and also 2677TT were found to be significantly associated withDrug-responsive idiopathic epilepsy.
ABCB1 G2677T/A polymorphism is associated with the risk of drug-resistant epilepsy in Asians
Relationship between ABCB1 3435TT genotype and antiepileptic drugs resistance in Epilepsy: updated systematic review and meta-analysis
TLDR
Results indicate that ABCB1 C3435T polymorphism, especially TT genotype, plays an important role in refractory epilepsy and genetic screening of this genotype may be useful to predict AEDs response before starting the treatment, as further investigations should validate the association.
Polymorphism in drug transporter gene ABCB1 is associated with drug resistance in Pakistani epilepsy patients
...
...

References

SHOWING 1-10 OF 66 REFERENCES
Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1.
TLDR
Patients with drug-resistant epilepsy were more likely to have the CC genotype at ABCB1 3435 than the TT genotype, implying that the polymorphism may not itself be causal but rather may be linked with the causal variant.
No association of ABCB1 polymorphisms with drug-refractory epilepsy in a north Indian population
Various Pharmacogenetic Aspects of Antiepileptic Drug Therapy
TLDR
Polymorphisms of drug targets may represent another genetic facet in epilepsy: a recent study demonstrated for the first time a polymorphism of a drug target associated in clinical practice with differing response to two classic AEDs.
ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients.
TLDR
It is demonstrated that ABCB1 polymorphisms may influence the AED responsiveness without significant changes in the plasma concentrations of CBZ, the inverse of previous results in European epileptics, thus the influence of ABCB 1 polymorphisms on the Aed responsiveness and/or the P-glycoprotein activity may vary among races.
Non-response to antiepileptic pharmacotherapy is associated with the ABCC2 −24C>T polymorphism in young and adult patients with epilepsy
TLDR
A higher risk of antiepileptic drug failure in ABCC2 −24T allele carriers is suggested possibly because of compensatory upregulation of ABCB1.
The clinical impact of pharmacogenetics on the treatment of epilepsy
TLDR
This article reviews the published work with particular emphasis on pharmacogenetic alterations that may affect efficacy, tolerability, and safety of antiepileptic drugs (AEDs), including variation in genes encoding drug target, drug transport, drug metabolizing, and human leucocyte antigen (HLA) proteins.
Association between ABCB1 C3435T polymorphism and drug-resistant epilepsy in Han Chinese
Clinical factors and ABCB1 polymorphisms in prediction of antiepileptic drug response: a prospective cohort study
Therapeutic Drug Monitoring and Clinical Outcomes in Epileptic Egyptian Patients: A Gene Polymorphism Perspective Study
TLDR
The adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) is an important candidate gene for potentially influencing the response to antiepileptic drugs and the utility of dose adjustment on the basis of genotype for these medicines that are substrates for this gene is assessed.
The Role of Pharmacogenetics in the Metabolism of Antiepileptic Drugs
  • U. Klotz
  • Biology, Medicine
    Clinical pharmacokinetics
  • 2007
TLDR
The traditional and validated therapeutic drug monitoring approach, representing a direct ‘phenotype’ assessment, still remains the method of choice when an individualised dosing regimen is anticipated, but pharmacogenetics and pharmacogenomics can offer some novel contributions when attempts are made to maximise drug efficacy and enhance drug safety.
...
...